ACAD vs PRAX
ACAD: Acadia Pharmaceuticals is a biopharmaceutical company specializing in the development and commercialization of innovative therapies for CNS disorders and rare diseases. PRAX: Praxis Precision Medicines is a clinical-stage biopharmaceutical company developing precision therapies for central nervous system disorders driven by neuronal imbalance.
Side-by-side fundamentals
| Metric | ACAD | PRAX | Edge |
|---|---|---|---|
| Price as of 2026-08-07 close | $29.21 | $360.76 | |
| Market cap as of 2026-08-10 | $5.0B | $10.1B | |
| P/E as of 2026-08-10 | 13.23 | n/a | |
| PEG as of 2026-08-10 | 2.28 | -5.38 | PRAX lower |
| Net margin as of 2026-08-10 | +33.4% | -2137.5% | ACAD higher |
| Gross margin as of 2026-08-10 | +91.1% | n/a | |
| Operating margin as of 2026-08-10 | +7.6% | -2340.3% | ACAD higher |
| ROE as of 2026-08-10 | +32.4% | -43.0% | ACAD higher |
| ROA as of 2026-08-10 | +24.4% | -40.2% | ACAD higher |
| Debt / equity as of 2026-08-10 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-08-10 | +47.0% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +27.5% | n/a | |
| Beta as of 2026-08-10 | 0.87 | 2.82 | |
| 1-year return as of 2026-08-07 close | +19.7% | +663.2% | PRAX higher |
Fundamentals: market data, as of 2026-08-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-07.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.